Status: Recruiting
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
A Phase 3, randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of paltusotine treatment vs placebo as well as the long-term safety of paltusotine in adults with carcinoid syndrome due to well-differentiated neuroendocrine tumors. The purpose of this study is to continue the evaluation of the safety, efficacy, and pharmacokinetics (PK) of paltusotine in participants with carcinoid syndrome.
Participants needed: 141
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Crinetics Pharmaceuticals Inc.Updated: Jun 25, 2026Locations: 51
Eligibility criteria
Male or female ≥18 years of age, at the time of Screening. [+5]
Diarrhea attributed to any condition(s) other than carcinoid syndrome. [+11]